Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Proyecto de Biomedicina CIMA SL is a holding company engaged in the provision of product licensing and intellectual property rights management services. It holds patents generated by the Centro de Investigacion Medica Aplicada, which have indications across the clinical fields of oncology, hepatology, dermatology, and gene therapy. The company was founded in June 2003 and is headquartered in Pamplona, Spain.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

ALX Oncology, Inc., part of ALX Oncology Holdings, Inc., is a company headquartered in Burlingame, CA. The firm operates as a clinical-stage immuno-oncology company which develops therapies for cancers. Jaume Pons is the current CEO of the firm.\nThe company says this about itself: ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to advance ALX148 into clinical development for the treatment of myelodysplastic syndromes and to continue clinical development for the treatment of a range of solid tumor indications.

Biocerox Products BV develops monoclonal antibodies directed at an immune checkpoint modulator. The company is headquartered in Utrecht, the Netherlands.

Beijing Xinkangchen Medical Technology Development Co., Ltd., established on 2002-02-05, Business scope includes medical devices(Three categories)manufacture;technology development,technology transfer,Technical Services,technical consulting;Sales of machinery and equipment,Groceries,Communication equipment(Except for radio transmitting equipment),Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals);Import and export,Technology Import and Export,Agent import and export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Part of Miltenyi GmbH, Miltenyi Biotec BV & Co. KG is a company headquartered in Bergisch Gladbach, Germany, that manufactures pharmaceutical products.

Reflection Therapeutics Ltd. is a company headquartered in Cambridge, UK, that engages in research and development on bio technology. The firm was founded in 2018.

Établissement Français du Sang collects, prepares, qualifies and distributes blood transfusion products. The company is headquartered in Saint-Denis, France.

Xiamen Bosay Gene Transcription Technology Co., Ltd., established on 2002-01-28, Business scope includes general items:Natural science research and experimental development;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;R&D and application of cell technology;Development of Human Gene Diagnosis and Therapy Technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology intermediary service;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Cosmetics Wholesale;Cosmetics Retail;Personal Hygiene Sales;Non-residential real estate leases.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).